Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

October 2, 2021

Study Completion Date

October 2, 2021

Conditions

HIV Infections

Interventions

DRUG

GSK3640254

GSK3640254 will be available as oral tablets.

DRUG

Darunavir/Ritonavir (DRV/RTV)

DRV/RTV will be available as oral tablets.

DRUG

Etravirine (ETR)

ETR will be available as oral tablets.

Trial Locations (1)

GSK Investigational Site, Austin